Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Percheron Therapeutics ( (AU:PER) ).
Percheron Therapeutics Limited has announced the date for its Annual General Meeting (AGM) on October 22, 2025, in Melbourne, Australia. The company has also released its FY 2025 Annual Report and looks forward to shareholder participation at the AGM. This announcement is part of Percheron’s ongoing efforts to engage with stakeholders and provide updates on its operations and strategic direction.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a publicly listed biotechnology company focused on developing and commercializing novel therapies for oncology and rare diseases. Its lead program, HMBD-002, is a monoclonal antibody targeting the immune checkpoint regulator, VISTA, which has completed a phase I clinical trial showing safety and tolerability.
Average Trading Volume: 3,569,710
Technical Sentiment Signal: Sell
Current Market Cap: A$11.42M
For detailed information about PER stock, go to TipRanks’ Stock Analysis page.